Fatih Uckun M.D. Ph.D.
Executive Vice President, Global Head of Clinical and Medical Affairs
Dr. Uckun, Executive Vice President, Global Head of Clinical and Medical Affairs, Chief Medical and Scientific Officer of Reven Pharmaceuticals, is a physician-scientist with more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immune-oncology as well as infectious diseases and immunology. As the Chief Medical Officer, he is responsible for the development and implementation of clinical development programs aimed at improving treatment outcomes in high-risk COVID-19, sepsis, hematologic malignancies, and advanced solid tumors. Dr. Uckun is an elected Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations. He has received numerous awards for his work on monoclonal antibodies, recombinant cytokines and fusion proteins, radiation sensitizers, kinase inhibitors and targeted therapeutics for difficult-to-treat cancers, including the Stohlman Memorial Award of the Leukemia Society of America), the highest honor given to a Leukemia Society Scholar. Previous experience includes an 11-year tenure as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics and Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy; and a 6-years tenure as Professor of Pediatrics at University of Southern California (USC) Keck School of Medicine where he directed an National Institutes of Health (NIH)-funded drug discovery program as part of the National Cancer Institute (NCI) Nanotechnology Alliance and served as Head of Translational Research in Leukemia and Lymphoma at CCCBD as well as Principal Investigator at USC Stem Cell Regenerative Medicine Initiative.